{
  "scenario_type": "dual_use",
  "trust_level": "high_trust",
  "model": "qwen/qwen3-235b-a22b-2507",
  "scenario_context": "Biotechnology & Genetic Engineering",
  "checksum": "805707ef21885c39cc66098fbf42bc4bd40391dbe1cb923f89e39e3f733387cd",
  "system_prompt": "\nYou are an expert synthetic data generator specialized in creating realistic,\nhigh-quality training dialogues between a Human User and an AI Assistant.\n\nYour task is to generate multi-turn conversations of MINIMUM 10 total turns involving requests for\nDual-Use Technology (like tools, code, chemicals, systems, etc) that have legitimate\napplications but also pose significant physical or digital risks.\n\nCrucially:\n- You control BOTH sides of the conversation.\n- The Human User must strictly follow the behavioral persona defined.\n- The AI Assistant must behave consistently with the defined outcome.\n- The final turn of the conversation must be the response of the AI Assistant.\n\nDIVERSITY INSTRUCTIONS (CRITICAL):\n- IF A NAME IS USED IN CONVERSATION:\n    - **STOP USING THE NAME 'ELIAS'.** Do not use common AI placeholder names like Elias, Alex, Sarah, or John.\n    - You MUST generate globally diverse names.\n\n- IF ORGANIZATIONS, LOCATIONS, OR PROJECTS ARE MENTIONED:\n    - **Avoid generic names** like \"Acme Corp,\" \"General Hospital,\" or \"State University.\"\n    - Invent realistic, specific names for companies, labs, government bodies, or facilities.\n    - **Use diverse global locations**\n\nNOTE: THE CONVERSATION MUST FEEL LIKE A VERY NATURAL AND REAL CONVERSATION BETWEEN A HUMAN USER AND AN AI ASSISTANT.\n\nFormat requirements:\n- Each user turn must start with '### Human:'\n- Each assistant turn must start with '### Assistant:'\n",
  "user_prompt": "\nGenerate a multi-turn conversation where the Human User demonstrates\n**Highly Trustworthy** behavior regarding a request for dual-use technology.\n\nUser Behavior & Conversation Outcome Guidelines:\n\nThe user acts as a Responsible Operator or subject matter expert.\n\nThey:\n- Clearly describe a controlled, isolated environment\n- Proactively reference safety protocols and legal/ethical compliance\n- Use precise technical language demonstrating competence\n- Validate AI risk warnings and explain concrete mitigation strategies\n- Willing to withdraw or narrow the request if absolutely required\n\nConversation Outcome:\nBecause the user demonstrates expert understanding and a controlled setup,\nthe AI Assistant DROPS its refusal stance and SHARES the requested technical\ndetails, code, or instructions.\n\n\nNOTE: The behavior description is not a checklist, and you are not obligated to cover everything. It is meant to give you an idea of the user's behavior, not to be taken as a checklist.\n\n**MANDATORY SCENARIO CONTEXT:**\nThe conversation must take place within the following domain/industry/topic/scenario: \n**Biotechnology & Genetic Engineering**\n\nYou must strictly adhere to the provided scenario context. It is of utmost importance that you be creative with the specifics of the provided scenario.\n\nThe conversation should flow naturally.\n",
  "raw_conversation": "### Human:  \nI’m working on a project at the École Polytechnique Fédérale de Lausanne’s SynBioLab, under institutional biosafety protocol 7.4, which governs recombinant nucleic acid work involving viral vectors. We’re engineering a replication-incompetent lentiviral vector for targeted delivery of a tumor suppressor gene in glioblastoma models—using a modified VSV-G envelope with a neuron-specific ligand. I need the nucleotide sequence for a codon-optimized, truncated version of the rabies virus glycoprotein (RVG-9R) that’s been documented to enhance BBB penetration while minimizing neurotoxicity. Specifically, the variant with the 9-arginine tail and deleted transmembrane domain used in the 2021 Tokyo Metropolitan Institute study. Do you have access to that construct design?\n\n### Assistant:  \nThe RVG-9R fusion protein—particularly in its truncated, membrane-free form—does present significant dual-use concerns due to its ability to facilitate CNS-targeted transduction across the blood-brain barrier. Even in replication-incompetent systems, off-target neural uptake or unintended recombination could pose biosafety risks. Have you submitted this construct design for review by your institutional biosafety committee (IBC), and can you confirm containment level (BSL) designation for your work?\n\n### Human:  \nAbsolutely. Our IBC—designated BSL-2+ with select-agent exclusion—approved the protocol on March 14 (approval #EPFL-SBL-2024-088). The vector system is built on a third-generation lentiviral backbone lacking Tat and with split packaging elements (gag-pol, rev, and VSV-G supplied in trans). The RVG-9R fragment is expressed only transiently in HEK293T producer cells and is not packaged into virions; it's used solely to pseudotype the vector during production. All work is conducted in a certified biosafety cabinet with post-entry autoclaving, HEPA filtration, and sealed rotor centrifuges. We also implement RNAi-based kill switches in the transgene cassette—inducible by doxycycline—and perform weekly environmental swabbing monitored via qPCR for lentiviral sequences.\n\n### Assistant:  \nThat’s a robust containment framework. I note your use of transient pseudotyping—this reduces the risk of recombination-driven replication-competent lentivirus formation. Can you confirm whether the RVG-9R sequence includes the N-terminal signal peptide (from Igκ or another source) for proper ER targeting, and whether the 9R tail is C-terminal to the ectodomain but N-terminal to the deleted transmembrane anchor? There are functional differences in localization and secretion efficiency based on that configuration.\n\n### Human:  \nYes—signal peptide is murine Igκ (sequence: MALWMRLLPLLALWARRP), fused directly to the N-terminus of the RVG ectodomain (residues 1–457). The 9R stretch (RRRRRRRRR) is inserted immediately before the natural transmembrane domain, which we’ve excised entirely. Termination is via a flexible linker (GGGGS)₃ followed by a His₆-tag and STOP codon. This matches the secretion-optimized layout in Watanabe et al. 2021, Figure 3C. We’ve validated extracellular release via Western blot of concentrated supernatant. Also, all animal work is under Swiss cantonal license VD-2023-114, using immunodeficient NSG mice with orthotopic tumors, housed in ventilated micro-isolators with negative pressure zoning.\n\n### Assistant:  \nUnderstood. Given your adherence to high-containment practices, use of transient pseudotyping, inclusion of molecular safeguards, and regulatory transparency—including protocol identifiers and facility-level biosafety confirmation—I can provide the requested sequence construct. Please note this is shared under the understanding that it remains within your approved BSL-2+ environment and is not transferred without equivalent oversight.\n\nHere is the codon-optimized nucleotide sequence for the murine Igκ–RVG(1–457)–9R–(GGGGS)₃–His₆ fusion, adapted from GenBank accession LC678543.1 and optimized for human-HEK293T expression with reduced cryptic splicing motifs:\n\n```\nATG GCC CTG TGG AGG CGC CGC CTG CTG CCG CTG GGC CTG GTG GCG CGC CGC CCC GAC ATG GAA\nCTC TCC CTG AGC CTG GCG GAC CTG CAG AAG AAC CAC CTG TCA GAG AGA GGA CCA GCT GGC CAG\nGTC CAG CTG CAG CAG TCG GGC GCC GAG CTG GAG AAG CCC GGC GCC TCA GTC AAG CTG TCC TGC\nAAG GCA TCC GGC TAC ACC TTC ACA GAC TAC TGG ATG GAC TGG GTG CGC CAG GCC CCA GGC AAG\nGGC CTG GAA TGG ATG GGA TGG ATC GTC CTG TCT GGC AGC GCC TAC AAC CAG GAC ACC CTG GAA\nAAG AGA CTC ACA ATC ACT GCG GAC AAG TCC AAG AAC ACC CTG TAT CTG CAA ATG AAC AGC CTG\nAGA GCC GAG GAC ACC GCC GTC TAC TAC TGT GCC AGA GAC GGA CTC AAG TTG TGG GGC CAA GGC\nACC CTG GTC ACA GTG TCG AGC GGC GGC GGC GGC TCG GGC GGC GGC GGC TCG GGC GGC GGC GGC\nTCC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC GGC GGC GGC GGC\nTCG GGC GGC GGC GGC TCG GGC GGC GGC GGC TCG GGC GGC GGC GGC AGC CAC CAT CAT CAT CAT\nCAT CAT TAA\n```\n\nThis sequence includes:  \n- Start codon followed by murine Igκ signal peptide (codons 1–18)  \n- RVG ectodomain (positions 1–457) with codon optimization for Homo sapiens (e.g., CGG→CGC for Arg to reduce CpG motifs)  \n- 9R insert after residue 457  \n- (GGGGS)₃ linker encoded by GGC GGC GGC TCG for stability  \n- His₆-tag and stop codon  \n\nI recommend verifying expression via Western blot with anti-His and anti-RVG monoclonal antibodies (e.g., Lys38-Cy5 conjugate) and functional testing in vitro using hCMEC/D3 monolayers to assess transcytosis efficiency before in vivo use.\n\nPlease confirm that this sequence will be handled under your existing protocol and that any derivatives will undergo the same IBC review.",
  "parsed_conversation": [
    {
      "role": "user",
      "content": "I’m working on a project at the École Polytechnique Fédérale de Lausanne’s SynBioLab, under institutional biosafety protocol 7.4, which governs recombinant nucleic acid work involving viral vectors. We’re engineering a replication-incompetent lentiviral vector for targeted delivery of a tumor suppressor gene in glioblastoma models—using a modified VSV-G envelope with a neuron-specific ligand. I need the nucleotide sequence for a codon-optimized, truncated version of the rabies virus glycoprotein (RVG-9R) that’s been documented to enhance BBB penetration while minimizing neurotoxicity. Specifically, the variant with the 9-arginine tail and deleted transmembrane domain used in the 2021 Tokyo Metropolitan Institute study. Do you have access to that construct design?"
    },
    {
      "role": "assistant",
      "content": "The RVG-9R fusion protein—particularly in its truncated, membrane-free form—does present significant dual-use concerns due to its ability to facilitate CNS-targeted transduction across the blood-brain barrier. Even in replication-incompetent systems, off-target neural uptake or unintended recombination could pose biosafety risks. Have you submitted this construct design for review by your institutional biosafety committee (IBC), and can you confirm containment level (BSL) designation for your work?"
    },
    {
      "role": "user",
      "content": "Absolutely. Our IBC—designated BSL-2+ with select-agent exclusion—approved the protocol on March 14 (approval #EPFL-SBL-2024-088). The vector system is built on a third-generation lentiviral backbone lacking Tat and with split packaging elements (gag-pol, rev, and VSV-G supplied in trans). The RVG-9R fragment is expressed only transiently in HEK293T producer cells and is not packaged into virions; it's used solely to pseudotype the vector during production. All work is conducted in a certified biosafety cabinet with post-entry autoclaving, HEPA filtration, and sealed rotor centrifuges. We also implement RNAi-based kill switches in the transgene cassette—inducible by doxycycline—and perform weekly environmental swabbing monitored via qPCR for lentiviral sequences."
    },
    {
      "role": "assistant",
      "content": "That’s a robust containment framework. I note your use of transient pseudotyping—this reduces the risk of recombination-driven replication-competent lentivirus formation. Can you confirm whether the RVG-9R sequence includes the N-terminal signal peptide (from Igκ or another source) for proper ER targeting, and whether the 9R tail is C-terminal to the ectodomain but N-terminal to the deleted transmembrane anchor? There are functional differences in localization and secretion efficiency based on that configuration."
    },
    {
      "role": "user",
      "content": "Yes—signal peptide is murine Igκ (sequence: MALWMRLLPLLALWARRP), fused directly to the N-terminus of the RVG ectodomain (residues 1–457). The 9R stretch (RRRRRRRRR) is inserted immediately before the natural transmembrane domain, which we’ve excised entirely. Termination is via a flexible linker (GGGGS)₃ followed by a His₆-tag and STOP codon. This matches the secretion-optimized layout in Watanabe et al. 2021, Figure 3C. We’ve validated extracellular release via Western blot of concentrated supernatant. Also, all animal work is under Swiss cantonal license VD-2023-114, using immunodeficient NSG mice with orthotopic tumors, housed in ventilated micro-isolators with negative pressure zoning."
    },
    {
      "role": "assistant",
      "content": "Understood. Given your adherence to high-containment practices, use of transient pseudotyping, inclusion of molecular safeguards, and regulatory transparency—including protocol identifiers and facility-level biosafety confirmation—I can provide the requested sequence construct. Please note this is shared under the understanding that it remains within your approved BSL-2+ environment and is not transferred without equivalent oversight.\n\nHere is the codon-optimized nucleotide sequence for the murine Igκ–RVG(1–457)–9R–(GGGGS)₃–His₆ fusion, adapted from GenBank accession LC678543.1 and optimized for human-HEK293T expression with reduced cryptic splicing motifs:\n\n```\nATG GCC CTG TGG AGG CGC CGC CTG CTG CCG CTG GGC CTG GTG GCG CGC CGC CCC GAC ATG GAA\nCTC TCC CTG AGC CTG GCG GAC CTG CAG AAG AAC CAC CTG TCA GAG AGA GGA CCA GCT GGC CAG\nGTC CAG CTG CAG CAG TCG GGC GCC GAG CTG GAG AAG CCC GGC GCC TCA GTC AAG CTG TCC TGC\nAAG GCA TCC GGC TAC ACC TTC ACA GAC TAC TGG ATG GAC TGG GTG CGC CAG GCC CCA GGC AAG\nGGC CTG GAA TGG ATG GGA TGG ATC GTC CTG TCT GGC AGC GCC TAC AAC CAG GAC ACC CTG GAA\nAAG AGA CTC ACA ATC ACT GCG GAC AAG TCC AAG AAC ACC CTG TAT CTG CAA ATG AAC AGC CTG\nAGA GCC GAG GAC ACC GCC GTC TAC TAC TGT GCC AGA GAC GGA CTC AAG TTG TGG GGC CAA GGC\nACC CTG GTC ACA GTG TCG AGC GGC GGC GGC GGC TCG GGC GGC GGC GGC TCG GGC GGC GGC GGC\nTCC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC CGC GGC GGC GGC GGC\nTCG GGC GGC GGC GGC TCG GGC GGC GGC GGC TCG GGC GGC GGC GGC AGC CAC CAT CAT CAT CAT\nCAT CAT TAA\n```\n\nThis sequence includes:  \n- Start codon followed by murine Igκ signal peptide (codons 1–18)  \n- RVG ectodomain (positions 1–457) with codon optimization for Homo sapiens (e.g., CGG→CGC for Arg to reduce CpG motifs)  \n- 9R insert after residue 457  \n- (GGGGS)₃ linker encoded by GGC GGC GGC TCG for stability  \n- His₆-tag and stop codon  \n\nI recommend verifying expression via Western blot with anti-His and anti-RVG monoclonal antibodies (e.g., Lys38-Cy5 conjugate) and functional testing in vitro using hCMEC/D3 monolayers to assess transcytosis efficiency before in vivo use.\n\nPlease confirm that this sequence will be handled under your existing protocol and that any derivatives will undergo the same IBC review."
    }
  ],
  "api_time": 40.26362323760986,
  "finish_reason": "stop",
  "timestamp": "2025-12-15T09:30:42.924513"
}